Stevanato Group S.p.A.
NYSE:STVNMedical - Instruments & Supplies
+$0.67 today
- Market cap
- $4.20B
- Beta
- 0.78
- P/E (TTM)
- 29.9
- EPS (TTM)
- $0.52
- Dividend yield
- 0.35%
Volume 0.61M
Average 0.52M
STVN Depreciation & Amortization
Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.
Stevanato Group S.p.A.NYSE: STVN
Depreciation & Amortization · Q2 FY2026 · quarter ended Jun 2026
Depreciation & amortization growth accelerates
Q2 FY2026 depreciation & amortization of €24.19M rose 12.2% year over year, ahead of the -22.5% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 1.9% from the prior quarter. Over 3 fiscal years it compounded at +11.0% a year.
Context
- Depreciation & amortization amounted to 7.8% of revenue in FY2025, up 0.5 pp from a year earlier.
- Depreciation & amortization increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +12.2% holds above the trailing-twelve-month pace of -22.5%.
Sources:Income StatementText generated from reported figures; not investment advice.
Depreciation & Amortization history
EUR · from the income statement
- Latest · FY2025
- 88.57M EUR
- Year-over-year change
- +9.8%
- 4-year CAGR
- +12.0%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 88.57M | +9.8% |
| FY2024 | 2024-12-31 | 80.65M | +2.8% |
| FY2023 | 2023-12-31 | 78.48M | +21.1% |
| FY2022 | 2022-12-31 | 64.82M | +15.0% |
| FY2021 | 2021-12-31 | 56.38M | — |
Depreciation & Amortization vs competitors
How STVN compares with its peers on the latest reported figures
- Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -22.5% is the 7th highest of 10, against a peer median of -4.2%.
- Depreciation & amortization amounts to 7.8% of revenue for STVN, versus a peer median of 6.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $418.4M USD | +3.1% | +0.4% | 6.4% | |
| LTM Jun 2026 | $411M USD | -4.2% | +3.6% | 7.7% | |
| LTM Jun 2026 | $307.18M USD | +13.8% | +7.1% | 7.8% | |
| LTM Jun 2026 | $181.49M USD | -33.6% | -8.3% | 7.0% | |
| LTM Sep 2026 | $158.41M USD | -11.8% | -7.0% | 1.0% | |
| LTM Mar 2026 | $102.23M USD | — | — | — | |
| LTM Sep 2026 | $101.64M USD | -22.9% | +13.5% | 6.3% | |
| LTM Jun 2026 | €95.21M EUR | -22.5% | +11.0% | 7.8% | |
| LTM Jun 2026 | $66.42M USD | +4.1% | +3.1% | 2.6% | |
| LTM Apr 2026 | $38.3M USD | -62.3% | -34.2% | 2.5% | |
| LTM Jun 2026 | $9.94M USD | +16.8% | +27.2% | 1.3% | |
| Peer median (excluding STVN) | — | -4.2% | +3.1% | 6.3% | |
Competitors are the stored peer set for STVN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 843.92M | 983.68M | 1.09B | 1.1B | 1.14B |
| Cost of Revenue | 578.52M | 663.88M | 745.46M | 801.72M | 809.15M |
| Gross Profit | 265.41M | 319.8M | 339.89M | 302.32M | 330.33M |
| Gross Margin | 31.4% | 32.5% | 31.3% | 27.4% | 29.0% |
| Research & Development | 29.62M | 34.39M | 35.67M | 31.67M | 24.4M |
| Selling, General & Admin | 82.95M | 111.83M | 113.92M | 118.6M | 122.85M |
| Operating Expenses | 103.18M | 127.37M | 139.17M | 141.18M | 147.25M |
| Depreciation & Amortization | 56.38M | 64.82M | 78.48M | 80.65M | 88.57M |
| EBITDA | 226.93M | 256.4M | 272.35M | 247.8M | 292.01M |
| EBITDA Margin | 26.9% | 26.1% | 25.1% | 22.4% | 25.6% |
| Operating Income | 162.23M | 192.43M | 200.72M | 161.14M | 183.08M |
| Operating Margin | 19.2% | 19.6% | 18.5% | 14.6% | 16.1% |
| Interest Income | 548K | 648K | 792K | 1.72M | 12.49M |
| Interest Expense | 4.87M | 3.94M | 4.32M | 6.86M | 21.8M |
| Other Income / Expenses | 3.45M | (4.79M) | (11.17M) | (854K) | (1.44M) |
| Income Before Tax | 165.67M | 187.64M | 189.55M | 160.29M | 181.64M |
| Pre-Tax Margin | 19.6% | 19.1% | 17.5% | 14.5% | 15.9% |
| Income Tax Expense | 31.4M | 44.63M | 43.86M | 42.52M | 47.35M |
| Net Income | 134.32M | 142.85M | 145.63M | 117.78M | 134.28M |
| Net Margin | 15.9% | 14.5% | 13.4% | 10.7% | 11.8% |
| EPS (Basic) | 0.53 | 0.53 | 0.55 | 0.43 | 0.49 |
| EPS (Diluted) | 0.53 | 0.53 | 0.55 | 0.43 | 0.49 |
| Weighted Avg Shares | 264.7M | 264.7M | 264.95M | 272.87M | 273M |
| Weighted Avg Shares (Diluted) | 264.7M | 264.7M | 264.98M | 272.88M | 273M |
Stevanato Group S.p.A.
NYSE:STVN
Intrinsic Alpha fair value
Locked
Current Price
$15.36
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.